Advertisement

After positive results from its multi-center, single dose Phase 3 clinical trial, Repligen Corp. has submitted a marketing authorization application to the European Medicines Agency (EMA) for its synthetic human secretin, SecreFlo, to be used with magnetic resonance imaging (MRI)s.

SOURCE

Advertisement
Advertisement